EN
登录

星球绿色控股公司收购注册乳铁蛋白免疫咀嚼片,加速进军不断增长的免疫健康市场

Planet Green Holdings Acquires Registered Lactoferrin Immunity Chewable Tablet, Accelerating Its Entry into Growing Immune-Health Market

CISION 等信源发布 2026-11-17 21:30

可切换为仅中文


Subsidiary Taihe Bio Acquires Formulation, Production Technology and Chinese Health Food Registration Rights for Bovine Colostrum, Vitamin C and Lactoferrin Chewable Tablets; Asset-Light Contract Manufacturing Model Targets a Faster, Capital-Efficient Path to Market

子公司太和生物收购牛初乳、维生素C和乳铁蛋白咀嚼片的配方、生产技术及中国保健食品注册权;轻资产合同制造模式旨在以更快速、资本更高效的方式推向市场

NEW YORK

纽约

,

,

Nov. 17, 2026

2026年11月17日

/PRNewswire/ -- Planet Green Holdings Corp. (NYSE American:

/美通社/ -- Planet Green Holdings Corp.(纽交所美国市场:

PLAG

瘟疫

) ('Planet Green' or the 'Company'), a diversified holding company, today announced that its wholly-owned subsidiary, Hubei Taihe Biotechnology Co., Ltd. ('Taihe Bio'), has entered into a technology transfer agreement with Harbin Aikesailun Biotechnology Co., Ltd. ('Aikesailun Bio') to acquire a registered immune-support health food product: Aikesailun-branded bovine colostrum, vitamin C and lactoferrin chewable tablets (the 'Product')..

)(“Planet Green”或“公司”),一家多元化控股公司,今日宣布其全资子公司湖北太和生物科技有限公司(“太和生物”)已与哈尔滨艾克赛伦生物科技有限公司(“艾克赛伦生物”)签订技术转让协议,以收购一款已注册的免疫支持类保健食品:艾克赛伦牌牛初乳、维生素C和乳铁蛋白咀嚼片(“该产品”)。

Under the agreement, Taihe Bio will acquire the Product's proprietary formulation, production process, quality standards and related technical know-how, together with the associated health food registration certificate rights in China.

根据协议,太和生物将收购该产品的专有配方、生产工艺、质量标准及相关技术诀窍,以及在中国相关的保健食品注册证书权利。

'This acquisition is a natural extension of our lactoferrin strategy,' said Mr. Bin Zhou, Chairman and Chief Executive Officer of Planet Green. 'Rather than starting from scratch, we are securing an already-registered health food formulation that brings together three well-recognized immune-support ingredients: lactoferrin, bovine colostrum and vitamin C.

“此次收购是我们乳铁蛋白战略的自然延伸,”Planet Green董事长兼首席执行官周斌先生表示。“我们无需从零开始,而是直接获得了一款已注册的健康食品配方,该配方融合了三种广受认可的免疫支持成分:乳铁蛋白、牛初乳和维生素C。”

This meaningfully strengthens our immunity product pipeline and moves us closer to delivering high-quality chewable tablet products to Chinese consumers. We believe it positions us well to capitalize on the continued growth of China's lactoferrin market.'.

这显著增强了我们的免疫产品管线,使我们更接近于向中国消费者提供高品质的咀嚼片产品。我们相信,这将使我们处于有利地位,以把握中国乳铁蛋白市场持续增长的机遇。

Key Highlights

核心亮点

Ready-made, registered product:

现成的已注册产品:

The Product already holds a health food registration in China. Obtaining a new registration can be a lengthy and costly process; acquiring one allows the Company to bypass much of that time and expense.

该产品已在中国获得保健食品注册。获取新的注册可能是一个漫长且昂贵的过程;通过收购现有注册,公司可以规避大部分时间和费用。

Development complete:

开发完成:

Laboratory-scale and pilot-scale development are finished, positioning the Product for the next phase of commercialization.

实验室规模和中试规模的开发已完成,为产品进入下一阶段的商业化奠定了基础。

Asset-light model:

轻资产模式:

Taihe Bio intends to use licensed contract manufacturers rather than build its own production facilities, designed to limit capital spending and speed time to market.

泰和生物计划采用授权合同制造商,而非自建生产设施,旨在限制资本支出并加快产品上市速度。

Builds on existing strategy:

在现有战略基础上构建:

The acquisition extends the Company's previously announced lactoferrin sourcing, marketing and distribution initiative and its chewable immunity tablet program.

此次收购扩展了公司此前宣布的乳铁蛋白采购、营销和分销计划,以及其咀嚼式免疫片剂项目。

Large, growing market:

庞大且不断增长的市场:

China held the largest country share of the global lactoferrin market in 2025, according to Grand View Research.

根据Grand View Research的数据,2025年中国在全球乳铁蛋白市场中占据最大的国家份额。

What Is Lactoferrin?

什么是乳铁蛋白?

Lactoferrin is a naturally occurring protein found in milk, with its highest concentrations in colostrum, the nutrient-rich 'first milk' produced in the days after birth. It is one of the body's natural defense proteins and is widely used as an ingredient in premium infant formula, immune-support supplements and sports nutrition products.

乳铁蛋白是一种天然存在于乳汁中的蛋白质,在初乳中浓度最高;初乳是出生后几天内产生的富含营养的“第一口奶”。它是人体天然的防御蛋白之一,被广泛用作高端婴儿配方奶粉、免疫支持补充剂以及运动营养产品的成分。

Because only small amounts can be extracted from milk, lactoferrin is a high-value specialty ingredient..

由于只能从牛奶中提取少量乳铁蛋白,因此它是一种高价值的特种成分。

The Product combines lactoferrin with two other well-known immune-support ingredients: bovine colostrum (the first milk produced by cows after calving) and vitamin C, in an easy-to-take chewable tablet format.

该产品将乳铁蛋白与另外两种知名的免疫支持成分——牛初乳(奶牛产犊后分泌的第一种乳汁)和维生素C相结合,制成易于服用的咀嚼片剂型。

Market Opportunity

市场机遇

According to Market Data Forecast, the global lactoferrin market is expected to grow from approximately US$278 million in 2026 to approximately US$519 million by 2034, representing a compound annual growth rate of approximately 8.1%. Grand View Research reports that China held the largest country share of that market in 2025..

根据Market Data Forecast的数据,全球乳铁蛋白市场预计将从2026年的约2.78亿美元增长至2034年的约5.19亿美元,复合年增长率约为8.1%。Grand View Research报告称,2025年中国在该市场中占据最大的国家份额。

Transaction and Next Steps

交易及后续步骤

Under the agreement, Aikesailun Bio will hand over technical documentation and provide process transfer support. The parties will jointly apply to China's State Administration for Market Regulation (SAMR) to transfer the registration certificate to Taihe Bio, which remains subject to regulatory approval.

根据协议,艾克赛伦生物将移交技术文件并提供工艺转移支持。双方将共同向中国国家市场监督管理总局(SAMR)申请将注册证书转让至泰合生物,该转让仍须获得监管批准。

Following the transfer, Taihe Bio intends to engage qualified contract manufacturers holding the required production licenses to bring the Product to commercial production..

转让完成后,太和生物拟委托持有必要生产许可证的合格合同生产商,实现产品的商业化生产。

About Planet Green Holdings Corp.

关于Planet Green Holdings Corp.

Planet Green Holdings Corp. ('Planet Green'), headquartered in Flushing, New York, is a Nevada holding company operating through its subsidiaries in China and Canada. Planet Green operates a diversified business portfolio ranging from consumer products to online advertising. For more information, please visit the Company's website at .

Planet Green Holdings Corp.(“Planet Green”)总部位于纽约法拉盛,是一家通过其在中国和加拿大的子公司开展业务的内华达控股公司。Planet Green 经营多元化的业务组合,涵盖从消费品到在线广告等多个领域。欲了解更多信息,请访问公司网站:。

www.planetgreenholdings.com

www.planetgreenholdings.com

.

。

Forward-Looking Statements

前瞻性陈述

This press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as 'anticipate,' 'believe,' 'expect,' 'estimate,' 'plan,' 'outlook,' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters.

本新闻稿包含1995年美国《私人证券诉讼改革法》“安全港”条款所定义的“前瞻性陈述”。前瞻性陈述可通过使用“预期”、“相信”、“期望”、“估计”、“计划”、“展望”和“预测”等词语以及其他类似表述来识别,这些词语或表述用于预测或指示未来事件或趋势,或不属于对历史事实的陈述。

Such statements are based on our management's current expectations and beliefs, as well as a number of assumptions concerning future events. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of our control, all of which could cause actual results to differ materially from those discussed in the forward-looking statements.

此类陈述基于我们管理层当前的预期和信念,以及有关未来事件的若干假设。此类前瞻性陈述受已知和未知的风险、不确定性、假设及其他重要因素的影响,其中许多因素超出我们的控制范围,所有这些因素都可能导致实际结果与前瞻性陈述中讨论的结果存在重大差异。

Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

因此,不应依赖前瞻性陈述来代表我们在任何后续日期的观点,且我们不承担更新前瞻性陈述以反映其作出日期之后发生的事件或情况的任何义务,无论是否因新信息、未来事件或其他原因所致,除非适用法律要求。

Factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in our reports filed with the U.S. Securities and Exchange Commission, which are available free of charge on the SEC's website at .

可能导致实际结果与前瞻性陈述中明示或暗示的结果存在重大差异的因素,详见我们向美国证券交易委员会(SEC)提交的报告,这些报告可在SEC网站(网址:)上免费获取。

www.sec.gov

www.sec.gov

.

。

Investor Relations Contact

投资者关系联系人

Planet Green Holdings Corp.

星球绿色控股公司

130-30 31st Avenue, Suite 512

31大道130-30号,512室

Flushing, NY 11354

纽约州法拉盛,邮编 11354

Tel: +1 347-370-2352

电话:+1 347-370-2352

www.planetgreenholdings.com

www.planetgreenholdings.com

SOURCE Planet Green Holdings Corp.

来源:Planet Green Holdings Corp.